Format

Send to

Choose Destination
Nat Rev Drug Discov. 2013 Jun;12(6):447-64. doi: 10.1038/nrd4010.

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Author information

1
Anticancer Antibody Team, Institut National de la Santé et de la Recherche Médicale U1052, Centre National de la Recherche Scientifique UMR 5286, Cancer Research Center of Lyon, Faculté Rockefeller, 8 Ave Rockefeller, 69008 Lyon, France. lars-petter.jordheim@univ-lyon1.fr

Abstract

Nucleoside analogues have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with cancer or viral infections. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Here, we review new nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response rates and reduced side effects. We also highlight the different approaches used in the development of these drugs and the potential of personalized therapy.

PMID:
23722347
DOI:
10.1038/nrd4010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center